title: Bone marrow derived stem cell therapy for type 2 diabetes mellitus.
abstract: In this study, 6 patients with type 2 diabetes (T2D) underwent autologous bone marrow mononuclear stem cell (BM-MNSC) infusion into the celiac and superior mesenteric arteries without pretreatment with any myeloablative or immune-suppressive therapy. Five of 6 (83%) showed normalization of their fasting glucose and the glycosylated hemoglobin (HbA1C) with significant reduction of their medication requirements. The HbA1C dropped on average 2.2 points. The three patients with diabetic complications showed improvement or stabilization and most patients reported improved energy and stamina. The durations of response varied between 6 months and 2 years. No patients had any significant adverse effects.
authors.affiliation: Hematology Department, the Lebanese Canadian and Notre Dame University Hospitals, Beirut, Lebanon.
authors.forename: Tarek
authors.initials: T
authors.lastname: Wehbe
authors.affiliation: Neurosurgery Department, the Lebanese Canadian Hospital, Beirut, Lebanon.
authors.forename: Nassim Abi
authors.initials: NA
authors.lastname: Chahine
authors.affiliation: Endocrinology Department, Al-Saydet Hospital, Zgharta, Lebanon.
authors.forename: Salam
authors.initials: S
authors.lastname: Sissi
authors.affiliation: Endocrinology Department, The Middle East and Notre Dame University Hospitals, Beirut, Lebanon.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Abou-Joaude
authors.affiliation: Endocrinology Department, the Lebanese Canadian Hospital, Beirut, Lebanon.
authors.forename: Louis
authors.initials: L
authors.lastname: Chalhoub
keywords: Type 2 diabetes (T2D); bone marrow mononuclear cells; glycosylated hemoglobin; stem cells